search
Back to results

Reduction of Progesterone Elevation at Trigger in POR After Long Acting COS Compared With Daily COS: a Prospective Randomized Trial (PE-PMA)

Primary Purpose

Infertility

Status
Unknown status
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Corifollitropin alfa
Follitropin Beta
Sponsored by
IRCCS San Raffaele
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Infertility

Eligibility Criteria

25 Years - 42 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Indication to IVF treatment
  • Normal BMI (18.5-24.9 kg/m2)
  • AMH level < 1.1 ng/ml and/or AFC < 5 follicles and/or < 3 oo-cytes retrieved in previous cycle
  • Regular menstrual cycles
  • Signed informed consent

Exclusion Criteria:

  • Freeze all cycles for abnormal bleeding
  • PCOS
  • History of untreated autoimmune
  • Endocrine or metabolic disorders
  • Ovarian cystectomy or oophorectomy
  • FSH ≥ 20 lU/L

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Corifollitropin alpha group

    FSH group

    Arm Description

    Patients treated with Corifollitropin-alpha in a long-acting controlled ovarian stimulation

    Patients treated with Follitropin beta in a daily controlled ovarian stimulation protocol

    Outcomes

    Primary Outcome Measures

    Premature progesterone elevation
    Progesterone > or equal to 1.1 ng/mL at day of trigger

    Secondary Outcome Measures

    Percentage of freeze-all cycles due to premature progesterone elevation
    Number of oocytes collected at ovum retrieval
    Fertilization rate
    Percentage of oocytes fertilized
    Number of embryos available
    Pregnancy rate
    Beta-HCG positive
    Ongoing pregnancy
    Vital fetus at 20 weeks of gestation

    Full Information

    First Posted
    December 1, 2020
    Last Updated
    January 7, 2021
    Sponsor
    IRCCS San Raffaele
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT04695483
    Brief Title
    Reduction of Progesterone Elevation at Trigger in POR After Long Acting COS Compared With Daily COS: a Prospective Randomized Trial
    Acronym
    PE-PMA
    Official Title
    Reduction of Progesterone Elevation at Trigger in Poor Responder Bologna' Criteria Patients After Controlled Ovarian Stimulation With Long Acting Standard Stimulation Protocol Compared With Conventional Daily Protocol: a Single Center Prospective Randomized Fase IV Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    December 2020
    Overall Recruitment Status
    Unknown status
    Study Start Date
    March 7, 2021 (Anticipated)
    Primary Completion Date
    August 30, 2022 (Anticipated)
    Study Completion Date
    February 28, 2023 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    IRCCS San Raffaele

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Product Manufactured in and Exported from the U.S.
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The overarching objective of this research is to generate clinical evidence to argue the benefits of long acting stimulation protocol compared to the daily stimulation protocol in poor ovarian responder bologna' criteria patients after controlled ovarian stimulation. Reduction in the proportion of subjects with progesterone > 1.1 ng/ml on the day of triggering (day + 13) in the experimental group compared to the control group is expected.
    Detailed Description
    Each patient will receive a first visit for infertility where will be collected subject history and baseline information, and meet all the inclusion / exclusion criteria. Eligible patients who agreed to participate will be randomized to either long acting standard COS with corifollitropin alpha or standard COS with daily FSH in a fixed GnRH antagonist protocol. All patients will be allowed to participate in the study only once and a written informed consent will be obtained from all, following consultation and before the initiation of the treatment. The endocrine profile of all the patients will be evaluated by analysis of serum progesterone, 17b-estradiol (E2), FSH and LH at different time points: basal condition, during stimulation, at the hCG day and at pick-up. Transvaginal follicular aspiration will be performed by ultrasound guidance 36 hours after hCG administration. The day of pick up oocytes will be fertilized with partner's semen; after 3-5 days, on the base of its evolution, embryo will be transferred. 14 days after embryo-transfer a preg-nancy test will be performed. Follow up in case of obtained pregnancy will be done until 20 weeks of gestation and considered as ongoing pregnancy. The entire duration of the study is 24 months, the follow up of the last patients enrolled will be 6 months.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Infertility

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    110 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Corifollitropin alpha group
    Arm Type
    Experimental
    Arm Description
    Patients treated with Corifollitropin-alpha in a long-acting controlled ovarian stimulation
    Arm Title
    FSH group
    Arm Type
    Active Comparator
    Arm Description
    Patients treated with Follitropin beta in a daily controlled ovarian stimulation protocol
    Intervention Type
    Drug
    Intervention Name(s)
    Corifollitropin alfa
    Intervention Description
    Controlled ovarian stimulation long-acting protocol
    Intervention Type
    Drug
    Intervention Name(s)
    Follitropin Beta
    Intervention Description
    Daily controlled ovarian stimulation protocol
    Primary Outcome Measure Information:
    Title
    Premature progesterone elevation
    Description
    Progesterone > or equal to 1.1 ng/mL at day of trigger
    Time Frame
    day 12
    Secondary Outcome Measure Information:
    Title
    Percentage of freeze-all cycles due to premature progesterone elevation
    Time Frame
    day 12
    Title
    Number of oocytes collected at ovum retrieval
    Time Frame
    day 14
    Title
    Fertilization rate
    Description
    Percentage of oocytes fertilized
    Time Frame
    day 15
    Title
    Number of embryos available
    Time Frame
    Day 17
    Title
    Pregnancy rate
    Description
    Beta-HCG positive
    Time Frame
    day 30
    Title
    Ongoing pregnancy
    Description
    Vital fetus at 20 weeks of gestation
    Time Frame
    Up to 20 weeks

    10. Eligibility

    Sex
    Female
    Gender Based
    Yes
    Minimum Age & Unit of Time
    25 Years
    Maximum Age & Unit of Time
    42 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Indication to IVF treatment Normal BMI (18.5-24.9 kg/m2) AMH level < 1.1 ng/ml and/or AFC < 5 follicles and/or < 3 oo-cytes retrieved in previous cycle Regular menstrual cycles Signed informed consent Exclusion Criteria: Freeze all cycles for abnormal bleeding PCOS History of untreated autoimmune Endocrine or metabolic disorders Ovarian cystectomy or oophorectomy FSH ≥ 20 lU/L
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Enrico Papaleo, MD
    Phone
    +390226436228
    Email
    papaleo.enrico@hsr.it
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Enrico Papaleo, MD
    Organizational Affiliation
    IRCCS San Raffaele
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Learn more about this trial

    Reduction of Progesterone Elevation at Trigger in POR After Long Acting COS Compared With Daily COS: a Prospective Randomized Trial

    We'll reach out to this number within 24 hrs